Back to Search

SynKIR-110 for Ovarian Cancer, Mesothelioma, or Cholangiocarcinoma

SynKIR-110 for Mesothelin Expressing Ovarian Cancer, Cholangiocarcinoma or Mesothelioma

Recruiting Phase 1 Interventional Study
Ovarian Cancer Cholangiocarcinoma Recurrent Mesothelioma, Malignant
More trials: Cancer clinical trials· Cancer trials in Florida
No Placebo Group Every participant receives an active treatment — no one gets a placebo.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Any
Trial phase
Phase 1
Study type
Interventional
Purpose
Treatment
Participants needed
42 (estimated)
Sponsor
Verismo Therapeutics · Industry
Who this trial is looking for

This trial is looking for adults with advanced ovarian cancer, mesothelioma, or cholangiocarcinoma who have had at least one previous treatment. Participants will receive a single intravenous dose of a treatment called SynKIR-110 to assess its safety and effectiveness.

Are You a Good Fit for This Trial?

You may be able to join if

  • I have been diagnosed with ovarian cancer, mesothelioma, or cholangiocarcinoma.
  • I am 18 years of age or older.
  • I have a performance status score of 0 to 1.
  • I have at least one measurable lesion.
  • My blood coagulation parameters are satisfactory.
  • My organ and bone marrow function are satisfactory.

You may not be able to join if

  • I have active invasive cancers other than my diagnosed cancer.
  • I have a history of T or B cell malignancies or previous gene-engineered T cell therapies.
  • I have sarcomatoid or biphasic mesothelioma.
  • I have any pulmonary issues.
  • I have a known immunodeficiency disease.
  • I have active hepatitis B, active hepatitis C, or any HIV infection.
  • I have an active autoimmune disease.

Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.

Think this trial could be right for you?

Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.

Check Your Eligibility
About This Trial

This first-in-human (FIH) trial is designed to assess the safety, feasibility, and potential activity of a single intravenous (IV) dose of SynKIR-110 administered to subjects with mesothelin-expressing advanced ovarian cancer, mesothelioma, and cholangiocarcinoma.

Trial Locations

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Pathologically confirmed recurrent or relapsed advanced ovarian cancer, primary peritoneal cancer, fallopian tube cancer, cholangiocarcinoma, or epithelial mesothelioma (pleural or peritoneal) after at least 1 prior line of systemic therapy for advanced disease * Adult 18 year…
Contacts

No contact information available.

NCT ID: NCT05568680 Source: ClinicalTrials.gov